Profile - To The Moon

JTMC1982

Jeniffer Tan Bee Chen

Posts · 10Posts · 10
Following · 0Following · 0
Followers · 0Followers · 0

- JTMC1982JTMC1982
  ·11-14
  $CN Energy Group Inc.(CNEY)$ Any hope? Still can holding this share?
  21 Comment
  1
  Share
  Report
- JTMC1982JTMC1982
  ·11-01
  How's the EC Healthcare? Still have opportunities to increase the share price?
  EC Healthcare (2138 HK): Shares at Multi-Year Low; Still Not a Value Buying Opportunity
  utm_source=tiger_community
  EC Healthcare (2138 HK): Shares at Multi-Year Low; Still Not a Value Buying Opportunity
  0 Comment
  Like
  Share
  Report
- JTMC1982JTMC1982
  ·10-08
  $EC HEALTHCARE(02138)$
  1 Comment
  Like
  Share
  Report
- JTMC1982JTMC1982
  ·2021-07-13
  $ContextLogic Inc.(WISH)$Look like the price will be ard $10.98~$11.05 and then up down up down still the same price…. Rubbish share
  129 Comment
  2
  Share
  Report
- JTMC1982JTMC1982
  ·2021-07-04
  $ContextLogic Inc.(WISH)$What’s going on…… please settle your disputes as fast so possible….
  100 Comment
  Like
  Share
  Report
- JTMC1982JTMC1982
  ·2021-06-18
  Oh no
  Orphazyme shares tumbled more than 60% in pre-market trading
  Orphazyme shares tumbled more than 60% in pre-market trading. Orphazyme slashed its financial foreca
  Orphazyme shares tumbled more than 60% in pre-market trading
  0 Comment
  4
  Share
  Report
- JTMC1982JTMC1982
  ·2021-06-17
  ?‍♀️
  Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
  ARK Invest's star stock picker is scooping up promising stocks that are trading well below recent highs.
  Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
  0 Comment
  Like
  Share
  Report
- JTMC1982JTMC1982
  ·2021-06-17
  Too little information and nothing to comment
  Sorry, this post has been deleted
  1 Comment
  2
  Share
  Report
- JTMC1982JTMC1982
  ·2021-06-17
  No confidence
  Sorry, this post has been deleted
  9 Comment
  4
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3582752686761306","uuid":"3582752686761306","gmtCreate":1622428174274,"gmtModify":1623895973198,"name":"JTMC1982","pinyin":"jtmc1982","introduction":"","introductionEn":null,"signature":"Jeniffer Tan Bee Chen","avatar":"https://static.tigerbbs.com/15b270f98d2377c6cc6f6662a939b1ed","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":19,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.61%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":2,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":370618848268640,"gmtCreate":1731522245408,"gmtModify":1731522248931,"author":{"id":"3582752686761306","authorId":"3582752686761306","name":"JTMC1982","avatar":"https://static.tigerbbs.com/15b270f98d2377c6cc6f6662a939b1ed","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3582752686761306","authorIdStr":"3582752686761306"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$</a> Any hope? Still can holding this share?","listText":"<a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$</a> Any hope? Still can holding this share?","text":"$CN Energy Group Inc.(CNEY)$ Any hope? Still can holding this share?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/370618848268640","isVote":1,"tweetType":1,"viewCount":21,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":366418112069656,"gmtCreate":1730465857089,"gmtModify":1730465860672,"author":{"id":"3582752686761306","authorId":"3582752686761306","name":"JTMC1982","avatar":"https://static.tigerbbs.com/15b270f98d2377c6cc6f6662a939b1ed","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3582752686761306","authorIdStr":"3582752686761306"},"themes":[],"htmlText":"How's the EC Healthcare? Still have opportunities to increase the share price?","listText":"How's the EC Healthcare? Still have opportunities to increase the share price?","text":"How's the EC Healthcare? Still have opportunities to increase the share price?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/366418112069656","repostId":"2450007653","repostType":2,"repost":{"id":"2450007653","weMediaInfo":{"introduction":"Smartkarma","home_visible":1,"media_name":"Smartkarma","id":"1009381084","head_image":"https://static.tigerbbs.com/bb92df7ff435380d798b36afa44a5c07"},"pubTimestamp":1720546879,"share":"https://ttm.financial/m/news/2450007653?lang=&edition=fundamental","pubTime":"2024-07-10 01:41","market":"us","language":"en","title":"EC Healthcare (2138 HK): Shares at Multi-Year Low; Still Not a Value Buying Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2450007653","media":"Smartkarma","summary":"utm_source=tiger_community","content":"<html><body><img src=\"https://static-prod.smartkarma.com/insight_cover_images/180f8232-2175-412c-9e77-174c9e170c0e.png\"/>\n<p>⬇  <a href=\"https://laohu8.com/S/02138\">EC Healthcare</a> - EC Healthcare reported muted FY24 result with sales up 9% but EBITDA and net profit down. Cost pressure and economic challenges contribute to uncertainties. Shares dropped 70% in the last one year.</p><br/><p>Continue reading on Smartkarma:- https://www.smartkarma.com/insights/ec-healthcare-2138-hk-shares-at-multi-year-low-still-not-a-value-buying-opportunity?utm_source=tiger_community</p><p>By Tina Banerjee, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/tina-banerjee?utm_source=tiger_community</p><p>On EC Healthcare (02138):- https://www.smartkarma.com/entities/ec-healthcare?utm_source=tiger_community</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EC Healthcare (2138 HK): Shares at Multi-Year Low; Still Not a Value Buying Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEC Healthcare (2138 HK): Shares at Multi-Year Low; Still Not a Value Buying Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1009381084\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/bb92df7ff435380d798b36afa44a5c07);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Smartkarma </p>\n<p class=\"h-time\">2024-07-10 01:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><img src=\"https://static-prod.smartkarma.com/insight_cover_images/180f8232-2175-412c-9e77-174c9e170c0e.png\"/>\n<p>⬇  <a href=\"https://laohu8.com/S/02138\">EC Healthcare</a> - EC Healthcare reported muted FY24 result with sales up 9% but EBITDA and net profit down. Cost pressure and economic challenges contribute to uncertainties. Shares dropped 70% in the last one year.</p><br/><p>Continue reading on Smartkarma:- https://www.smartkarma.com/insights/ec-healthcare-2138-hk-shares-at-multi-year-low-still-not-a-value-buying-opportunity?utm_source=tiger_community</p><p>By Tina Banerjee, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/tina-banerjee?utm_source=tiger_community</p><p>On EC Healthcare (02138):- https://www.smartkarma.com/entities/ec-healthcare?utm_source=tiger_community</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.smartkarma.com/home/private-investor-solutions/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2450007653","content_text":"⬇  EC Healthcare - EC Healthcare reported muted FY24 result with sales up 9% but EBITDA and net profit down. Cost pressure and economic challenges contribute to uncertainties. Shares dropped 70% in the last one year.Continue reading on Smartkarma:- https://www.smartkarma.com/insights/ec-healthcare-2138-hk-shares-at-multi-year-low-still-not-a-value-buying-opportunity?utm_source=tiger_communityBy Tina Banerjee, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/tina-banerjee?utm_source=tiger_communityOn EC Healthcare (02138):- https://www.smartkarma.com/entities/ec-healthcare?utm_source=tiger_community","news_type":1},"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":357802865750208,"gmtCreate":1728374538175,"gmtModify":1728374540996,"author":{"id":"3582752686761306","authorId":"3582752686761306","name":"JTMC1982","avatar":"https://static.tigerbbs.com/15b270f98d2377c6cc6f6662a939b1ed","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3582752686761306","authorIdStr":"3582752686761306"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/02138\">$EC HEALTHCARE(02138)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/02138\">$EC HEALTHCARE(02138)$</a>&nbsp;","text":"$EC HEALTHCARE(02138)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/357802865750208","isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145935096,"gmtCreate":1626185617815,"gmtModify":1703755102970,"author":{"id":"3582752686761306","authorId":"3582752686761306","name":"JTMC1982","avatar":"https://static.tigerbbs.com/15b270f98d2377c6cc6f6662a939b1ed","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3582752686761306","authorIdStr":"3582752686761306"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>Look like the price will&nbsp;be ard&nbsp;$10.98~$11.05 and&nbsp;then up down up down still the same price…. Rubbish share","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>Look like the price will&nbsp;be ard&nbsp;$10.98~$11.05 and&nbsp;then up down up down still the same price…. Rubbish share","text":"$ContextLogic Inc.(WISH)$Look like the price will be ard $10.98~$11.05 and then up down up down still the same price…. Rubbish share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/145935096","isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155191493,"gmtCreate":1625383931112,"gmtModify":1703741122517,"author":{"id":"3582752686761306","authorId":"3582752686761306","name":"JTMC1982","avatar":"https://static.tigerbbs.com/15b270f98d2377c6cc6f6662a939b1ed","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3582752686761306","authorIdStr":"3582752686761306"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>What’s&nbsp;going on…… please&nbsp;settle your disputes as fast so possible….","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>What’s&nbsp;going on…… please&nbsp;settle your disputes as fast so possible….","text":"$ContextLogic Inc.(WISH)$What’s going on…… please settle your disputes as fast so possible….","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/155191493","isVote":1,"tweetType":1,"viewCount":100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166607935,"gmtCreate":1624004745027,"gmtModify":1703826322386,"author":{"id":"3582752686761306","authorId":"3582752686761306","name":"JTMC1982","avatar":"https://static.tigerbbs.com/15b270f98d2377c6cc6f6662a939b1ed","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3582752686761306","authorIdStr":"3582752686761306"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166607935","repostId":"1142916683","repostType":4,"repost":{"id":"1142916683","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624003342,"share":"https://ttm.financial/m/news/1142916683?lang=&edition=fundamental","pubTime":"2021-06-18 16:02","market":"us","language":"en","title":"Orphazyme shares tumbled more than 60% in pre-market trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1142916683","media":"Tiger Newspress","summary":"Orphazyme shares tumbled more than 60% in pre-market trading.\nOrphazyme slashed its financial foreca","content":"<p>Orphazyme&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;60% in pre-market&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b722b82c7d6ab2a6fcc7364eb2517b7f\" tg-width=\"1293\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.</p>\n<p>Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.</p>\n<p>As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.</p>\n<p>\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.</p>\n<p>Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme shares tumbled more than 60% in pre-market trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme shares tumbled more than 60% in pre-market trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-18 16:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Orphazyme&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;60% in pre-market&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b722b82c7d6ab2a6fcc7364eb2517b7f\" tg-width=\"1293\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.</p>\n<p>Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.</p>\n<p>As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.</p>\n<p>\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.</p>\n<p>Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142916683","content_text":"Orphazyme shares tumbled more than 60% in pre-market trading.\nOrphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.\nOrphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.\nAs a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.\n\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.\nOrphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.","news_type":1},"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161609009,"gmtCreate":1623920301401,"gmtModify":1703823525868,"author":{"id":"3582752686761306","authorId":"3582752686761306","name":"JTMC1982","avatar":"https://static.tigerbbs.com/15b270f98d2377c6cc6f6662a939b1ed","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3582752686761306","authorIdStr":"3582752686761306"},"themes":[],"htmlText":"?‍♀️","listText":"?‍♀️","text":"?‍♀️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161609009","repostId":"2143794095","repostType":4,"repost":{"id":"2143794095","pubTimestamp":1623892525,"share":"https://ttm.financial/m/news/2143794095?lang=&edition=fundamental","pubTime":"2021-06-17 09:15","market":"us","language":"en","title":"Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2143794095","media":"Motley Fool","summary":"ARK Invest's star stock picker is scooping up promising stocks that are trading well below recent highs.","content":"<p>No one consistently lit up the market the way ARK Invest's Cathie Wood did last year. The ace stock picker saw her exchange-traded funds (ETFs) soar in 2020, but her collection of disruptive growth stocks has fallen out of favor since mid-February.</p>\n<p>Wood is making the most of the correction in dynamic companies. On Tuesday she increased her positions in <b>DraftKings</b> (NASDAQ:DKNG), <b>JD.com</b> (NASDAQ:JD), and <b><a href=\"https://laohu8.com/S/PATH\">UiPath</a></b>&nbsp;(NYSE:PATH). Let's take a closer look at her shopping list.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1cff5e8a545a25eace4bc6b4d22b6ac5\" tg-width=\"700\" tg-height=\"467\"><span>Image source: Getty Images.</span></p>\n<h2>DraftKings</h2>\n<p>Fantasy sports is a gateway drug to real-money wagering, and no <a href=\"https://laohu8.com/S/AONE.U\">one</a> is playing this game better than DraftKings. The platform that offers cash prizes for picking optimal starting league lineups is also using its popularity with competitive sports fans to prop up its growing sportsbook operations.</p>\n<p>Revenue rose 90% last year, a pretty amazing feat in a pandemic year where many seasons were delayed and shortened. Revenue soared 253% in the first quarter of this year, better-than-expected results even if the comparisons were going to be kind given the sporting world calamity that started in March of last year.</p>\n<p>DraftKings stock tumbled as much as 12% on Tuesday -- recovering to a more acceptable 4% decline by the close -- after becoming the latest short target of noted worrywart Hindenburg Research. The negative report alleges that one of the merger partners behind DraftKings hitting the market last year has a history of black-market gaming, money laundering, and organized crime. It could prove problematic if still relevant, but Wood apparently added to her DraftKings position during Tuesday's down day.</p>\n<h2>JD.com</h2>\n<p>Wood has been trimming her exposure to many of China's best-known growth stocks, but JD.com has been the exception. She has added to China's largest online retailer (in terms of revenue) on back-to-back trading days. It goes to show that investing in Chinese stocks&nbsp;isn't simply a matter of yes or no, as it's a more nuanced decision.</p>\n<p>Revenue growth decelerated to a 25% clip in 2019, but JD.com is starting to press down on the accelerator. Net revenue rose 29% last year, soaring 39% through the first three months of 2021. It's the kind of momentum you like to see in any growth stocks, and this is a good sign that -- despite unloading a lot of shares of Chinese growth stocks through May -- she's not giving up on the world's most populous nation.</p>\n<h2>UiPath</h2>\n<p>There are a couple of names scattered among Wood's ETFs that weren't even public when the year began. ARK Invest isn't afraid to buy into new issues while they still have that new stock smell, and that's where UiPath comes in. The provider of enterprise software for robotics went public at $56 just two months ago. The stock closed at $70 on Tuesday, but it was trading as high as $90 just three weeks ago. Wood doesn't let downticks sway her from investing in promising companies, and UiPath fits that bill.</p>\n<p>Revenue rose 81% in fiscal 2021, climbing 65% in the first quarter of fiscal 2022. UiPath isn't expected to turn a profit until 2024 at the earliest, but flush with nearly $1.9 billion in cash after its springtime IPO it has more than enough dry powder to stay in the fight until it gets there.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 09:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/16/cathie-wood-goes-bargain-hunting-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>No one consistently lit up the market the way ARK Invest's Cathie Wood did last year. The ace stock picker saw her exchange-traded funds (ETFs) soar in 2020, but her collection of disruptive growth ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/16/cathie-wood-goes-bargain-hunting-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DKNG":"DraftKings Inc.","JD":"京东","PATH":"UiPath"},"source_url":"https://www.fool.com/investing/2021/06/16/cathie-wood-goes-bargain-hunting-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143794095","content_text":"No one consistently lit up the market the way ARK Invest's Cathie Wood did last year. The ace stock picker saw her exchange-traded funds (ETFs) soar in 2020, but her collection of disruptive growth stocks has fallen out of favor since mid-February.\nWood is making the most of the correction in dynamic companies. On Tuesday she increased her positions in DraftKings (NASDAQ:DKNG), JD.com (NASDAQ:JD), and UiPath (NYSE:PATH). Let's take a closer look at her shopping list.\nImage source: Getty Images.\nDraftKings\nFantasy sports is a gateway drug to real-money wagering, and no one is playing this game better than DraftKings. The platform that offers cash prizes for picking optimal starting league lineups is also using its popularity with competitive sports fans to prop up its growing sportsbook operations.\nRevenue rose 90% last year, a pretty amazing feat in a pandemic year where many seasons were delayed and shortened. Revenue soared 253% in the first quarter of this year, better-than-expected results even if the comparisons were going to be kind given the sporting world calamity that started in March of last year.\nDraftKings stock tumbled as much as 12% on Tuesday -- recovering to a more acceptable 4% decline by the close -- after becoming the latest short target of noted worrywart Hindenburg Research. The negative report alleges that one of the merger partners behind DraftKings hitting the market last year has a history of black-market gaming, money laundering, and organized crime. It could prove problematic if still relevant, but Wood apparently added to her DraftKings position during Tuesday's down day.\nJD.com\nWood has been trimming her exposure to many of China's best-known growth stocks, but JD.com has been the exception. She has added to China's largest online retailer (in terms of revenue) on back-to-back trading days. It goes to show that investing in Chinese stocks isn't simply a matter of yes or no, as it's a more nuanced decision.\nRevenue growth decelerated to a 25% clip in 2019, but JD.com is starting to press down on the accelerator. Net revenue rose 29% last year, soaring 39% through the first three months of 2021. It's the kind of momentum you like to see in any growth stocks, and this is a good sign that -- despite unloading a lot of shares of Chinese growth stocks through May -- she's not giving up on the world's most populous nation.\nUiPath\nThere are a couple of names scattered among Wood's ETFs that weren't even public when the year began. ARK Invest isn't afraid to buy into new issues while they still have that new stock smell, and that's where UiPath comes in. The provider of enterprise software for robotics went public at $56 just two months ago. The stock closed at $70 on Tuesday, but it was trading as high as $90 just three weeks ago. Wood doesn't let downticks sway her from investing in promising companies, and UiPath fits that bill.\nRevenue rose 81% in fiscal 2021, climbing 65% in the first quarter of fiscal 2022. UiPath isn't expected to turn a profit until 2024 at the earliest, but flush with nearly $1.9 billion in cash after its springtime IPO it has more than enough dry powder to stay in the fight until it gets there.","news_type":1},"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161600324,"gmtCreate":1623920267268,"gmtModify":1703823524406,"author":{"id":"3582752686761306","authorId":"3582752686761306","name":"JTMC1982","avatar":"https://static.tigerbbs.com/15b270f98d2377c6cc6f6662a939b1ed","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3582752686761306","authorIdStr":"3582752686761306"},"themes":[],"htmlText":"Too little information and nothing to comment","listText":"Too little information and nothing to comment","text":"Too little information and nothing to comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161600324","repostId":"1183583910","repostType":4,"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163722748,"gmtCreate":1623894169384,"gmtModify":1703822783498,"author":{"id":"3582752686761306","authorId":"3582752686761306","name":"JTMC1982","avatar":"https://static.tigerbbs.com/15b270f98d2377c6cc6f6662a939b1ed","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3582752686761306","authorIdStr":"3582752686761306"},"themes":[],"htmlText":"No confidence&nbsp;","listText":"No confidence&nbsp;","text":"No confidence","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163722748","repostId":"1148768572","repostType":2,"isVote":1,"tweetType":1,"viewCount":9,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}